Research
Hormonal
SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardiovascular protection and should be prioritized in women with type 2 diabetes and high cardiovascular risk.
If you have diabetes and heart risk factors, ask your doctor about SGLT2 inhibitors (like Jardiance/Farxiga) or GLP-1 agonists (like Ozempic/Victoza). These drugs protect your heart and kidneys beyond just lowering blood sugar. Standard sugar-lowering pills may not be enough for heart protection.
StrongSupportsVERY_HIGH confidence
The use of pharmacological therapy to address these risk factors, especially some pleiotropic antihyperglycemic drugs, may provide additional options for the prevention of cardiovascular disease.
Why this rating
Supported by multiple large RCTs (EMPA-REG, CANVAS, DECLARE, LEADER, SUSTAIN-6) cited in the text.
Source
Principles of cardiovascular risk management in perimenopausal women with type 2 diabetes
Ф. О. Ушанова et al. · FOCUS Endocrinology · 2023
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →